Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.
Neal D Shore, Karim Fizazi, Michael Thomas Schweizer...
https://pubmed.ncbi.nlm.nih.gov/42108644/Actively Recruiting
Led by Pfizer · Updated on 2026-10-30
900
Participants Needed
231
Research Sites
61 weeks
Total Duration
Researchers are evaluating the investigational drug PF-06821497 mevrometostat combined with enzalutamide compared to enzalutamide alone in men with metastatic castration-resistant prostate cancer mCRPC who have not previously received certain systemic treatments. This global, multicenter, randomized Phase 3 study focuses on participants who have mCRPC but have only received androgen deprivation therapy or first-generation anti-androgen agents, excluding prior treatment with androgen receptor signaling inhibitors such as enzalutamide or abiraterone. Participants are randomly assigned to one of two groups one receiving PF-06821497 twice daily plus enzalutamide once daily, and the other receiving a placebo twice daily plus enzalutamide once daily. The study includes several phases screening, randomization, treatment, safety follow-up, and long-term follow-up. Treatment is continuous oral dosing during the treatment phase. Throughout the study, participants will undergo regular assessments including scans, laboratory tests, and patient-reported questionnaires to measure outcomes such as radiographic progression-free survival, overall survival, pain progression, prostate specific antigen levels, and quality of life. Safety is monitored continuously, and follow-up can last up to approximately five years after randomization to evaluate long-term effects and treatment impact.
CONDITIONS
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
P
Pfizer CT.gov Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pfizer
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | PF‑06821497 + enzalutamide | Placebo + enzalutamide | Enzalutamide alone |
|---|---|---|---|
| What it is | An investigational small‑molecule EZH2 inhibitor (PF‑06821497) taken orally twice daily plus standard oral enzalutamide | Placebo tablets given orally alongside standard oral enzalutamide | Enzalutamide alone is an established androgen receptor pathway inhibitor commonly used in ARPI‑naïve mCRPC |
| Role in trial | Experimental treatment arm testing PF‑06821497 added to enzalutamide | Control arm receiving matching placebo plus enzalutamide | Represents typical current treatment option for ARPI‑naïve mCRPC |
| Primary use | Test whether adding PF‑06821497 to enzalutamide improves radiographic progression‑free survival and overall survival | Comparator for measuring efficacy of investigational agent when added to enzalutamide | Serves as reference for standard ARPI‑based treatment in practice |
| Administration | Oral PF‑06821497 twice daily plus oral enzalutamide once daily | Oral placebo twice daily plus oral enzalutamide once daily | Oral enzalutamide once daily as monotherapy |
| Evidence status | Efficacy is being evaluated in the randomized MEVPRO‑2 trial; not yet known | Serves as control arm; efficacy of enzalutamide alone established in prior studies | Enzalutamide monotherapy has demonstrated overall survival benefit in mCRPC |
| Important risks | Safety profile is under investigation; risks not yet fully characterizable | Risks reflect those of enzalutamide; placebo adds no pharmacologic risk | Enzalutamide has known risks including fatigue, hypertension, falls, and cognitive effects |
| Important limitations | Efficacy and safety results are not yet available until trial completion | Placebo control may not reflect real‑world single‑agent use without trial context | Evidence reflects historical use and may evolve as new therapies emerge |
| Patient impact | Not yet established until trial results are available | Provides the standard ARPI backbone for measuring impact in trial | Enzalutamide monotherapy has demonstrated quality‑of‑life and survival benefits in mCRPC |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 3 years
Participants receive either PF-06821497 plus enzalutamide or placebo plus enzalutamide as assigned randomly.
Regular visits as scheduled by the study team
Duration - Duration varies per participant
Participants are monitored for safety after treatment ends.
Follow-up visits to assess safety
Duration - Up to approximately 5 years after randomization
Participants are followed for long-term outcomes including survival and quality of life.
Periodic visits for assessments
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Neal D Shore, Karim Fizazi, Michael Thomas Schweizer...
https://pubmed.ncbi.nlm.nih.gov/42108644/Pfizer
Lead Sponsor